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Abstract 
Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the 
antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase 
inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib, vatalanib) with their intratumoral 
distribution data obtained by matrix-assisted laser desorption ionization mass spectrometry 
imaging (MALDI-MSI). In the first mouse model, only sunitinib exhibited broad-spectrum 
antivascular and antitumor activities by simultaneously suppressing vascular endothelial growth 
factor receptor-2 (VEGFR2) and desmin expression, and by increasing intratumoral hypoxia and 
inhibiting both tumor growth and vascularisation significantly. Importantly, the highest and most 
homogeneous intratumoral drug concentrations have been found in sunitinib-treated animals. In 
another animal model, where - in contrast to the first model - vatalanib was detectable at 
homogeneously high intratumoral concentrations, the drug significantly reduced tumor growth 
and angiogenesis. In conclusion, the tumor tissue penetration and thus the antiangiogenic and 
antitumor potential of antiangiogenic RTKIs vary among the tumor models and our study 
demonstrates the potential of MALDI-MSI to predict the efficacy of unlabelled small molecule 
antiangiogenic drugs in malignant tissue. Our approach is thus a major technical and preclinical 
advance demonstrating that primary resistance to angiogenesis inhibitors involves limited tumor 
tissue drug penetration. We also conclude that MALDI-MSI may significantly contribute to the 
improvement of antivascular cancer therapies. 
Key words: matrix assisted laser desorption ionization, imaging mass spectrometry, angiogenesis, receptor 
tyrosine kinase inhibitor, resistance, cancer 
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Introduction 
Since an adequate blood supply is regarded as 
essential for tumor growth [1], there had been 
overwhelming optimism that targeting angiogenic 
pathways would represent an effective treatment 
strategy in solid tumors. Receptor tyrosine kinase 
inhibitors (RTKIs) represent a major class of drugs 
that have been developed to block tumor-induced 
angiogenesis. In the current study, we investigated 
the in vivo antitumor and antivascular activities and 
the tumor tissue drug distribution data of five 
different RTKIs (motesanib, pazopanib, sorafenib, 
sunitinib, vatalanib). Out of these five compounds, 
pazopanib, sorafenib and sunitinib have already been 
approved by the FDA for advanced renal cancer [2-4]. 
Additionally, pazopanib is effective in advanced soft 
tissue sarcoma [2] and sorafenib is available for the 
treatment of unresectable liver cancer and locally 
recurrent or metastatic, progressive differentiated 
thyroid carcinoma refractory to radioactive iodine 
treatment [3]. Furthermore, sunitinib is approved in 
progressive well-differentiated pancreatic 
neuroendocrine tumors and gastrointestinal stromal 
tumors after disease progression, or intolerance to 
imatinib mesylate [4]. The two not yet approved 
drugs, motesanib and vatalanib, are currently 
investigated in clinical trials. The only study 
completed so far with motesanib in first- or second 
line-treated colon cancer patients presents modest 
efficacy [5], while vatalanib is showing promising 
results in colon cancer patients only with increased 
vessel density or low lactate dehydrogenase levels 
[6-8]. Altogether, although initial results with 
antiangiogenic RTKIs looked promising and some of 
them were approved in the early 2000s, subsequent 
preclinical and clinical studies provided 
disappointing survival data [9-12]. The limited 
efficacy of antiangiogenic agents has prompted 
research into the possible causes behind the resistance 
against antiangiogenics with the expectation of 
developing novel and more successful therapeutic 
approaches. The previously described resistance 
mechanisms include the development of a more 
malignant phenotype associated with 
therapy-induced hypoxia, VEGF-independent 
endothelial growth driven by various pro-angiogenic 
cytokines, the mobilization of bone marrow-derived 
proangiogenic hematopoietic cells or endothelial 
progenitors and increased tumor invasiveness due to 
vessel cooption [9-13]. However, the lack of greater 
clinical success is, at least in part, also due to our 
limited knowledge on the pharmacokinetic profile, 
bioavailability and distribution of these drugs at the 
tumor site as the so far published studies have 
focused mainly on the measurements of compounds 
from the blood, urine and occasionally from tissue 
homogenates [14].  
Herein, we utilize mouse models of cancer and 
matrix-assisted laser desorption ionization mass 
spectrometry imaging (MALDI-MSI) to study the 
intratumoral levels and distribution of antiangiogenic 
RTKIs. We also investigate tumor growth and 
vascularization, intratumoral hypoxia, tumor 
capillary wall integrity and the tumor and vascular 
cell expressions of the target receptors of 
antiangiogenic RTKIs.  
Materials and Methods 
Drugs 
For the in vivo treatments, we selected five 
different antiangiogenic RTKIs potently inhibiting not 
only the main angiogenic receptor, vascular 
endothelial factor receptor-2 (VEGFR2), but also 
platelet-derived growth factor (PDGF) and fibroblast 
growth factor (FGF) receptors [15-19]. All drugs were 
purchased from the LC Laboratories (Woburn, MA, 
USA; CAS numbers: motesanib: 453562-69-1, 
pazopanib: 444731-52-6, sorafenib: 284461-73-0, 
sunitinib: 557795-19-4, vatalanib: 212141-54-3) at >99% 
purity and were suspended in 2% 
carboxymethylcellulose with 2 mg/mL 
methyl-4-hydroxibenzoate (both from Sigma Aldrich) 
before treatments. The administration and treatment 
dose for each compound were established to be 
tolerable and effective according to the literature [15, 
20-35]. Control mice received only the suspending 
medium.  
In vivo tumor models and treatments  
The C26 mouse colon adenocarcinoma cell line 
was cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum and 1% 
penicillin/streptomycin (all from Sigma Aldrich, 
Steinheim, Germany) in a humidified atmosphere at 
37°C and 5% CO2. Groups of six 8-week-old female 
Balb/C mice from our colony were inoculated 
subcutaneously (s.c.) with 2x106 C26 cells, as 
described recently [36]. All RTKI treatments began 2 
weeks after tumor cell injection and were performed 
once daily at a dose of 100 mg/kg p.o. with a feeding 
tube 5 times a week for two weeks. 
The C38 mouse colorectal carcinoma was 
maintained by serial s.c. transplantations in 
8-week-old female C57Bl/6 mice, as previously 
described [37, 38]. Tumor tissue was cut into cubes 
measuring 5×5×5 mm. Animals were anesthetized 
and one piece of tumor tissue was transplanted into 
the back of each mouse. Treatments began 13 days 
after tumor implantation and were performed 
similarly to that of the C26 model.  
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Tumor size was measured three times a week 
with a caliper and expressed in mm3 by the formula 
for the volume of a prolate ellipsoid (length x width2 
π/6) in case of both in vivo models, as described 
previously [39].  
To assess intratumoral hypoxia, a bolus of i.p. 
pimonidazole (60 mg/kg; Hypoxyprobe Inc., MA, 
USA) was administered 2 hours before the mice were 
sacrificed in both animal models. Two hours after the 
last RTKI treatment, blood was drawn from the 
canthus and the animals were sacrificed. Tumors were 
removed and snap frozen, as described previously [4]. 
All animal experiments were carried out in 
accordance with the ARRIVE guidelines [40] and with 
the animal welfare regulations of the host institutes 
(permission number: 22.1/722/3/2010).  
Compound characterization 
Drugs were dissolved in 50% methanol 
(Sigma-Aldrich, Steinheim, Germany) at HPLC grade 
(99.8+%) at 0.5 mg/mL concentration. The matrix (7.5 
mg/mL α-cyano-4-hydroxycinnamic acid, Sigma 
Aldrich, Steinheim, Germany) was dissolved in 50% 
acetonitrile at hypergrade for liquid chromatography– 
mass spectrometry (LC-MS, Merck, Darmstadt, 
Germany) and 0.1% trifluoroacetic acid 
(Sigma-Aldrich, Steinheim, Germany). 1μL of the 
compound solution was applied with 1μL matrix 
solution to the MALDI plate. Full mass spectra were 
obtained by using a MALDI LTQ Orbitrap XL mass 
spectrometer (Thermo Fisher Scientific, Bremen, 
Germany) at 60,000 resolution in positive polarity 
mode. The spots were sampled in survey mode 
collecting 20 experiments for a single run. The 
nitrogen laser was set to 10 μJ. The detected precursor 
ion was fragmentized by using 40% normalized 
collision energy (NCE) during a 30 ms activation time, 
while activation Q of 0.250 was applied. The precursor 
ions were isolated with m/z 2.0 width and MS/MS 
spectra were collected at normal scan rate in centroid 
mode.  
Tissue imaging of antiangiogenic RTKIs 
10-μm frozen sections were cut using a cryotome 
and placed onto glass slides. After drying of the 
tissue, 0.5 mL matrix solution was applied stepwise to 
avoid wetting of the sections by using an airbrush, 
while its position was kept constant. Full mass spectra 
were collected by using the Orbitrap mass analyzer at 
60,000 resolution (at m/z 400) in positive mode with a 
150−800 Da mass range with activated automatic gain 
control mode. Tissue sections were sampled with 100 
μm raster size. The nitrogen laser was operated at 10.0 
μJ. For obtaining MS/MS data, the observed peaks of 
the parent antiangiogenic drugs were isolated with 
m/z 2.0 width isolation window and fragmentized, 
using 40% NCE, 30 ms activation time and 0.250 
activation Q. For MS/MS spectra generation, the 
minimal signal required was 500 counts, the fragment 
ions were analyzed in the linear ion trap at normal 
scan rate. Evaluation of the spectra was performed 
with Xcalibur v 2.0.7. software, while the visualization 
of the drug and fragment ion distribution was 
implemented with the ImageQuest™ software (both 
from Thermo Fisher Scientific, San José, CA). 
Quantification of the precursor compounds 
For tissue quantification of intratumoral drug 
concentration, calibration curves of each compound 
were established on tissue sections of untreated 
control C26 and C38 tumors. After determining the 
detection limit of the instrument, drugs were 
dissolved and diluted in 50% methanol (concentration 
range: 0.001–0.5 μmol·mL−1) and 0.5 μL from each 
concentration was applied on the tissue section. 
Spraying and detection conditions were the same as 
those during the tissue section analysis of in vivo 
treated tumors. Average signal intensities of the 
applied concentrations were measured and 
normalized to Total Ion Current (TIC) by using 
Xcalibur v 2.0.7. and ImageQuest™ softwares. 
Calibration curves were created (Figure S1) and then 
used to estimate the tissue drug concentrations of in 
vivo-treated tumor sections. 
Compound detection in the blood 
20μL of plasma sample was analyzed. Plasma 
proteins were removed by acetonitrile precipitation. 
Pierce C18 Tips (Thermo Fisher Scientific, Rockford, 
IL, USA) were used to concentrate the RTKIs from the 
precipitated plasma samples following the 
manufacturer’s instructions. 1μL of the sample was 
applied on the MALDI plate with 1μL matrix solution 
using the same instrument settings as those for the 
compound characterization.  
Throughout our MS experiments drugs were 
considered to be identified if the precursor molecule 
and at least one fragment ion were discovered in the 
spectra.  
Analysis of vascular parameters and target 
receptors 
For the analysis of RTKI distributions, vascular 
parameters and target receptor expressions, 10 serial 
frozen sections were cut from each tumor (Figure S2). 
Sections #5 and #7 were used to analyze the 
distribution of the given RTKI by MALDI-MSI and for 
subsequent haematoxylin&eosin (HE) staining. 
Sections #1-4 were labeled with either of the following 
primary antibodies: anti-FGFR1, anti-PDGFRα, 
anti-PDGFRβ and anti-VEGFR2. For hypoxia 
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detection (section #6), we used the Hypoxyprobe-1 
Plus Kit. Sections #8-10 were labeled with either of the 
following primary antibodies: anti-laminin (for 
endothelial basement membrane labeling), 
anti-desmin and anti-α-smooth muscle actin 
(anti-αSMA) (both for pericyte labeling). All of the 
above primary antibodies were developed with an 
appropriate fluorescent secondary antibody. Primary 
and secondary antibodies and reagents used for 
immunofluorescence are listed in Table S1.  
For intratumoral microvessel area 
measurements, sections #1-4, #6 and #8-10 were 
co-stained with anti-mouse CD31 antibody, followed 
by a counterstain with Hoechst 33342 before 
mounting under glass coverslips in ProlongGold 
Antifade Reagent (20 μL, Invitrogen, Carlsbad, CA, 
USA; Catalog number: P36930). Slides were scanned 
by TissueFAXS (TissueGnostics GmbH, Vienna, 
Austria) and analyzed by ImageJ and TissueGnostics 
4.0.0140 (TissueGnostics GmbH, Vienna, Austria) 
softwares. Images of ten different necrosis-free 
intratumoral regions were assessed separately for 
each section. Microvessel areas were then calculated 
by counting the number of CD31-positive pixels in the 
total area of ten intratumoral regions. The percentages 
of microvessels that were positive for laminin, desmin 
or αSMA were also calculated. For quantification of 
VEGFR2 expression, the average numbers of VEGFR2 
positive endothelial or tumor cells were calculated. 
For quantification of hypoxia and PDGFRα, PDGFRβ 
and FGFR1 expressions, the percentages of hypoxic 
regions and positively labeled cells were determined 
across the entire area of section. 
Statistical analysis  
Differences in parametric and non-parametric 
variables between multiple groups were analyzed 
using ANOVA and Dunnett's posthoc test or using 
the Kruskal–Wallis test followed by a posthoc Dunn’s 
multiple comparison test, respectively. For comparing 
two groups, t- or Mann-Whitney U tests were applied. 
Differences were considered statistically significant 
when P<0.05. All Statistical analyses were carried out 
using GraphPad Prism 5.0 software (GraphPad Inc., 
San Diego, CA, USA).  
Figure 1 shows the flowchart of the experiments. 
 
 
Figure 1. Graphical abstract of the study procedure. Ten serial frozen sections were cut from C26 and C38 mouse tumors treated with five different antiangiogenic RTKIs. 
Sections were used then to analyze drug dispersal by MALDI-MSI and, moreover, for HE staining and immunolabeling with antibodies against CD31, laminin, desmin, αSMA and 
the target receptors of RTKIs (VEGFR2, PDGFRα, PDGFRβ and FGFR1). An additional slide was also used for hypoxia detection. After scanning the tissue sections, the antitumor 
and antivascular properties of RTKIs were correlated with their tumor tissue distribution data obtained by MALDI-MSI. 
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Table 1. Chemical properties of the studied drugs 
 Motesanib Pazopanib Sorafenib Sunitinib Vatalanib 
Chemical formula C22H23N5O 
 
C21H23N7O2S 
 
C21H16ClF3N4O3 C22H27FN4O2 
 
C20H15ClN4 
 
Molecular weight (g/mol) 373.45 
 
437.52 
 
464.82 398.47 346.81 
Monoisotopic mass [M+H]+ (m/z) 374.199 
 
438.170 
 
465.093 
 
399.218 
 
347.105 
Fragment ions (m/z) 212.1; 189.1; 163.1 
 
421.1; 357.1; 342.1 
 
447.1; 425.1; 270.2; 252.2 326.1; 283.1 320.2 
311.2 
294.2 
268.1 
254.1 
220.2 
 
 
Results 
MALDI-MSI is an eligible tool to characterize 
antiangiogenic RTKIs in malignant tissue 
Monoisotopic mass and fragmentation pattern of 
each drug compound were defined on a MALDI 
target plate. When applied to the tissue surface, drug 
molecules showed similar ionization and 
fragmentation properties to those generated on the 
MALDI plate: the same monoisotopic masses and 
fragment ions detected on both surfaces are shown in 
Table 1.  
The monoisotopic mass of motesanib was 
detected at m/z 374.199. Fragmentation of the 
molecule resulted in ions at m/z 212.1, which 
corresponds to the split at the amide bond of 
nicotinamide. The fragment ions corresponding to the 
indoline formamide moiety were identified at m/z 
189.1. Cleavage of the pyridine moiety and charge 
retention resulted fragment ions at m/z 163.1.  
Pazopanib was detected at m/z 438.17. 
Subsequent MS/MS fragmentation of the precursor 
ions led to the loss of the amidogen group, generating 
fragment ions at m/z 421.1. Further loss of the sulfur 
dioxide eventuated fragment ions at m/z 357.1, while 
the presence of fragment ions at m/z 342.1 indicated 
the loss of an additional methyl group. 
Sorafenib was found with a monoisotopic mass 
of m/z 465.093. Dehydroxylation of the formamide 
moiety and subsequent bond retention resulted in 
fragment ions at m/z 447.1, while cleavage of the 
pyridine ring eventuated fragment ions at m/z 425.1. 
Fragmentation of the molecule also led to detection of 
ions at m/z 270.2, corresponding to the loss of the 
chloro-trifluoromethyl-phenylamine group. Presence 
of fragment ions at m/z 252.2 indicated the cleavage of 
the chloro-trifluoromethyl-phenyl ring and the 
scission of the carboxamide group.  
Sunitinib was identified at m/z 399.218 with 
fragment ions at m/z 326.1 and 283.1, in line with a 
recently published study from our group [36].  
The monoisotopic mass of vatalanib was present 
at m/z 347.105. Scission of the benzene ring resulted in 
the generation of ions at m/z 320.2. Loss of the chloride 
eventuated fragment ions at m/z 311.2, while 
decomposition of the phthalazin-amine ring led to the 
detection of ions at m/z 294.2. Loss of the pyridine 
moiety resulted in fragment ions at m/z 268.1, while 
cleavage of the methylpiridyne group indicated the 
detection of ions at m/z 254.1. Loss of the 
chlorophenil-amine group resulted in fragment ions 
at m/z 220.2. Chemical properties of drug compounds 
are shown in Table 1. 
Antiangiogenic RTKI concentration and 
distribution show drug- and tumor 
type-specific variations in malignant tissue  
Calibration of the drug molecules resulted in 
linear correlation between concentration and 
normalized average signal intensity for all 
compounds in the examined concentration range 
(Figure S1). In both animal models, all the five drugs 
absorbed successfully with notable signal intensities 
being observed in the peripheral blood (data not 
shown). Because of the possibility of generating 
nonspecific precursor ion peaks from the tissue itself, 
the average signal intensities obtained from 
RTKI-treated tumors were compared with the average 
signal intensities of non-treated control tumors. Based 
on the calibration curves, average signal intensities 
were translated into drug concentration (μmol/mL) 
data. While intratumoral sorafenib and vatalanib 
levels did not differ between drug-treated and control 
C26 tumors, the concentrations of motesanib, 
sunitinib and pazopanib were significantly elevated 
(vs. control), with the highest values detected in the 
sunitinib-treated animals (P<0.05 for all comparisons; 
Figure 2).  
Importantly, the above described drug 
concentrations refer to the entire tumor section and 
striking differences in the drug distribution were 
observable within the in vivo-treated tumors. As for 
sunitinib, the drug was always homogeneously 
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distributed within the viable C26 tumor areas and 
necrotic regions showed notably lower signal 
intensities (Figure 3 and Figure S3). In contrast, 
motesanib was seen only in one third of the C26 
tumors at relatively high levels in connected areas and 
the intratumoral distributions of this RTKI and 
pazopanib (both of which were also present at 
relatively high average tumor tissue levels in C26 
tumors; Figure 2) were inhomogeneous with the 
highest signal intensities observed in necrotic areas 
(Figure S3). Only traces of sorafenib and vatalanib 
were detected in the C26 model. Notably, motesanib, 
pazopanib and sorafenib were detected only at 
trace-level in C38 tumors. Representative images of 
intratumoral antiangiogenic RTKI distributions are 
shown in Figure 3. 
In a previously published study, we found 
significantly decreased C38 tumor burdens in 
C57Bl/6 mice treated with vatalanib [38]. 
Accordingly, in order to investigate why mice bearing 
C26 tumors respond notably poorer to vatalanib than 
those with C38 tumors, we also utilized MALDI-MSI 
of C38 tumors and addressed whether there are 
animal model-specific variations in the tumor tissue 
penetration and distribution of antiangiogenic RTKIs. 
In contrast to the C26 model, in C38 tumors, besides 
sunitinib, vatalanib was also well-distributed with 
notable signal intensities (Figure 3). In line with this, 
in vatalanib-treated mice bearing C38 tumors, the 
intratumoral drug concentration was significantly 
higher than that in the group of untreated controls 
(P=0.0006, Figure 2). It is also important to mention 
that we found significantly higher vatalanib 
concentrations in C38 than in C26 tumors (0.116 
µmol/mL vs 0.178 nmol/mL, P=0.0025).  
 
Figure 2. Tumor tissue concentrations of antiangiogenic RTKIs. Signal intensities (normalized to TIC) of the appropriate RTKIs in treated tumors and the same non-specific 
normalized m/z values measured in control tumors were used to calculate intratumoral drug concentrations. Data are shown as box (first and third quartiles) and whisker 
(maximum to minimum) plots with the mean (horizontal bar) from 6 animals per group. 
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Figure 3. Representative images of drug distribution in C26 and C38 tumors after two weeks of treatment with different antiangiogenic RTKIs. Precursor ion signals of RTKIs 
were normalized to TIC. 
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Figure 4. In vivo growth inhibition of C26 and C38 tumors. Balb/C (C26) and 
C57Bl/6 (C38) mice were randomized to receive either vehicle (n=6) or 100 mg/kg 
RTKI (n=6/subgroup) treatment p.o. 5 times a week for two weeks. Out of the five 
different antiangiogenic RTKIs (motesanib, pazopanib, sorafenib, sunitinib and 
vatalanib), only sunitinib reduced significantly the in vivo growth of C26 mouse colon 
adenocarcinoma cells in Balb/C mice (a). In the C38 model, besides sunitinib, vatalanib 
also demonstrated a significant growth-inhibitory effect (b). Growth curves are 
means for six mice per group; bars, SEM. Mean tumor volumes at the beginning of 
treatments were 155.3±25.4 mm3 and 376.9±51.2 mm3 in the C26 and C38 models, 
respectively. *P=0.0018, **P=0.0048 
 
 
Intratumoral levels and distribution of 
antiangiogenic RTKIs critically determine their 
antitumor potential 
The growth of s.c. tumors in mice is known to be 
angiogenesis-dependent [41]. Thus, next we assessed 
the antivascular and antitumor activities of the five 
different antiangiogenic RTKIs (motesanib, 
pazopanib, sorafenib, sunitinib and vatalanib) in 
Balb/C and C57Bl/6 mice bearing s.c. syngeneic C26 
and C38 tumors, respectively. Strikingly, and in line 
with the drug concentration and distribution data 
presented above, C26 tumor burden was reduced 
significantly only in sunitinib-treated animals 
(P=0.0018) and no significant growth-inhibitory effect 
of motesanib, pazopanib, sorafenib or vatalanib was 
observed (Figure 4). In accordance with its significant 
antitumor potential, sunitinib showed the broadest 
spectrum of antivascular activity in the C26 model: it 
significantly increased intratumoral hypoxia 
(P=0.0152; Figure 5) and suppressed microvessel areas 
(P<0.0001; Figure 6) and VEGFR2 and pericyte desmin 
expressions (P=0.0353 and P=0.0135, respectively; 
Figures S4-5). As shown in Figure 6 and Figure S5, 
significantly decreased microvessel areas (in case of 
motesanib and sorafenib, P<0.05) and desmin 
expressions (in case of motesanib; P<0.05) were also 
observed sporadically in the other treatment groups. 
Nevertheless, in contrast to the potent antitumor 
activity of sunitinib against C26 tumors, none of these 
random antivascular effects did translate into a 
significant tumor burden-suppressing potential in the 
C26 model (Figure 4). 
 
 
 
Figure 5. Graph (a) and 
representative images (b) of hypoxic 
area ratios in the C26 model. 
Hypoxic area ratios are shown in 
the percentage of the total tumor 
section. Green, anti-pimonidazole 
staining for hypoxia; blue, nuclear 
staining with Hoechst. *P=0.0152 
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Figure 6. Microvessel areas of mouse C26 (a, b) and C38 (c, d) tumors. Antiangiogenic RTKI-treated C26 (a) and C38 (c) tumors were labeled with the endothelial cell marker 
CD31 (red) and with Hoechst33342 (as nuclear counterstain; blue). Microvessel areas of C26 (b) and C38 (d) tumors were calculated by counting the number of CD31-positive 
pixels in the total area of ten intratumoral regions. In (b and d), data are shown as box (first and third quartiles) and whisker (maximum to minimum) plots with the mean 
(horizontal bar) from 6 animals per group. *P<0.05; **P<0.03 
 
C26 tumors were also immunohistochemically 
characterized for pericyte αSMA (Figure S6), laminin 
(an endothelial basement membrane component; 
Figure S7) and, besides VEGFR2 (Figure S4), for 
additional target receptors of the tested drugs (i.e. for 
PDGFRα, PDGFRβ and FGFR1; Figure S8-9). 
However, no statistically significant differences were 
detected in the tumor tissue expressions of these 
markers between control animals and mice in any of 
the RTKI treatment groups (data not shown). 
Because vatalanib did not influence tumor 
growth or vascularization in the C26 model in the 
current study, next we sought to recapitulate the 
significant antitumor effects of vatalanib 
demonstrated earlier by our group in the C38 model 
[38]. As expected, we observed a robust and 
significant growth-inhibitory effect of vatalanib when 
administered to C57Bl/6 mice bearing 
subcutaneously growing C38 tumors (P=0.0048; 
Figure 4). In addition, a significant decrease of 
intratumoral microvessel areas was also observed for 
vatalanib in the C38 model (P<0.03, Figure 6). These 
results are of crucial importance because, as 
mentioned above, although vatalanib was not present 
with a relevant intratumoral distribution and thus did 
not show antiangiogenic or antitumor activity in the 
C26 model, this RTKI was well-distributed with 
notable signal intensities in C38 tumors (Figure 3). 
Importantly, besides vatalanib, sunitinib also exerted 
significant antitumor (P=0.0048, Figure 4) and 
antivascular (P<0.03, Figure 6) activities in the C38 
model. However, similarly to the C26 model - and in 
line with the above described poor intratumoral 
distributions of motesanib, pazopanib and sorafenib 
(Figure 3), no significant tumor growth inhibitory 
(Figure 4) or antiangiogenic (Figure 6) effects were 
observed when C38 tumor-bearing mice were treated 
with any of these latter three RTKIs. 
Discussion 
Although there are different concepts explaining 
resistance to angiogenesis inhibition [9, 10], the 
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significance of insufficient tumor tissue drug 
penetration in primary resistance to antiangiogenic 
treatments has not yet been explored. Based on our 
current results, we propose that the intratumoral 
concentration and distribution and thus the 
antivascular and antitumor potential of 
antiangiogenic RTKIs are tumor model-specific and, 
moreover, that primary resistance to these drugs 
involves inadequate tumor tissue drug penetration.  
Preclinical studies investigating the efficacy of 
combined antiangiogenic and cytotoxic chemotherapy 
treatments have provided promising results on 
intratumoral drug distributions of chemotherapeutic 
agents [42, 43]. However, clinical trials evaluating 
antiangiogenic drugs in patients with solid 
malignancies have been disappointingly modest [9, 
10], and recent clinical data raised serious concern 
that bevacizumab (a humanized anti-VEGF antibody) 
can significantly reduce the uptake of chemotherapy 
by human tumors [44]. Of note, this is in contrast to 
the "vessel normalization theory" proposed by Jain 
and colleagues whereby treatment with an 
antiangiogenic agent such as bevacizumab [45] 
normalizes the chaotic tumor blood vessel network 
thus increasing chemotherapeutic drug delivery. It is 
also unclear whether antiangiogenic RTKIs - which 
are typically used as monotherapies in the indications 
for which they are so far approved (e.g. renal and liver 
cancers) - can efficiently penetrate tumor tissue and 
can reach all of the intratumoral areas. To the best of 
our knowledge, this is the first study reporting the 
head-to-head comparison of the intratumoral 
concentrations and distributions of various unlabeled 
antiangiogenic RTKIs by MSI. We found that oral 
administration of motesanib, pazopanib, sorafenib, 
sunitinib or vatalanib resulted in the absorption of all 
the five drugs with notable signal intensities being 
observed in the circulation. Surprisingly, only 
motesanib, pazopanib and sunitinib treatments 
resulted in significantly elevated intratumoral drug 
levels in the C26 model with the highest 
concentrations and the most homogeneous tumor 
tissue distributions observed in sunitinib-treated 
animals. The intratumoral distributions of motesanib 
and pazopanib were less homogeneous and notable 
signal intensities were confined to necrotic areas of 
C26 tumors. While reasons for these differences 
remain unclear, a possible explanation is that some 
antiangiogenic RTKIs given at standard doses may 
impair the efficacy of their own tumor tissue uptake 
and distribution. This phenomenon of reduced tumor 
blood capillary network functionality (i.e. “impaired 
capillary normalization”) by some of the tested RTKIs 
could be the consequence of the applied standard 
drug doses and treatment schedules that had been 
approved for maximal antivascular effects with 
tolerable host toxicity but not for vessel 
normalization. In line with this assumption, improved 
chemotherapeutic drug delivery was reported at 
reduced but not at standard antiangiogenic drug 
doses [46]. Importantly, however, tumor samples 
analyzed at the beginning (day 1) of antiangiogenic 
RTKI treatments (data not shown) demonstrated 
similar drug distribution patterns to that observed in 
tumors treated for two weeks. Thus, the 
aforementioned assumption of impaired capillary 
normalization caused by long-term antiangiogenic 
RTKI treatment is not supported by our findings.  
Furthermore, one could also assume that since 
PDGF-B is a key survival factor for the pericyte 
population and pericytes have a crucial role in the 
maintenance of vascular stability [47], RTKIs with 
potent anti-PDGFRβ activity may not promote 
normalization but, instead, might destabilize the 
vasculature and thus interfere with drug delivery. 
Our actual findings, however, do not support this 
assumption: treatment with sunitinib (the tested RTKI 
with the lowest IC50 value against PDGFRβ, [18]) 
significantly decreased the pericyte coverage of tumor 
capillaries (as assessed by desmin expression). 
Notably, because all the five investigated RTKIs are 
highly bound to plasma proteins [48-51], it is also 
unlikely that their distinctive intratumoral 
distributions are due to their different plasma 
protein-binding profile.  
In C26 tumors, the most homogeneous 
intratumoral drug patterns have been observed in 
sunitinib-treated animals but only traces of vatalanib 
were detected. In contrast, besides sunitinib, vatalanib 
was always detectable at homogeneously high 
concentrations throughout the malignant tissue in the 
C38 model. Chances, therefore, are that besides their 
dose, schedule and direct antivascular activity, the 
phenotype of the host vasculature and/or the tumor 
type are also likely to influence the tumor tissue levels 
and distribution of antiangiogenic RTKIs. The 
possible mechanisms linking inadequate 
antiangiogenic RTKI tumor concentration and 
endothelial- and tumor-specific characteristics involve 
lysosomal degradation of RTKIs [52] and increased 
RTKI efflux by the tumor [53] or the endothelial [54] 
cells or both. 
There is a substantial volume of literature on the 
potential mechanisms that can lead to tumor 
resistance against antiangiogenic RTKIs [55]. These 
include hypoxia-driven mechanisms, the activation of 
compensatory angiogenic molecular pathways, the 
mobilization of myeloid or endothelial progenitor cell 
populations, the downregulation of target receptors in 
endothelial or tumor cells and also a switch to an 
 Theranostics 2017, Vol. 7, Issue 2 
 
 
http://www.thno.org 
410 
alternative vascularization mechanism such as 
intussusceptive angiogenesis [38] or vessel-cooption 
[13]. Although suboptimal pharmacokinetics have 
been also described [56], so far most studies dealing 
with antiangiogenic RTKIs and drug resistance in 
solid tumors have focused on the above mechanisms. 
The key finding of the current study is that in 
comparison with tumor tissue drug concentrations, 
intratumoral distribution of antiangiogenic RTKIs 
critically determines their therapeutic efficacy. 
However, it is also important to mention here that 
besides their activity exerted on the tumor vessels, 
antiangiogenic RTKIs may also have direct antitumor 
effects via inhibition of one or more target receptors 
expressed by the tumor cells (Figures S4, S8-S9). As 
the tumor mass grows and the given antiangiogenic 
RTKI exerts its antivasular effects, blood capillaries 
may become nonfunctional or separated by longer 
distances resulting in limited drug delivery to RTK 
expressing tumor cells located distally from 
functional blood capillaries. Thus, the net result of 
antiangiogenic RTKI treatment in solid tumors might 
be tightly balanced by the (potentially opposing) 
antivascular and direct antitumor effects of these 
drugs.  
Nevertheless, as mentioned above, in addition to 
sprouting angiogenesis (the main target of 
antiangiogenic drugs), it is today evident that tumors 
can acquire their vasculature also via alternative 
(non-sprouting) mechanisms [9], including 
vasculogenic mimicry [57], intussusceptive 
microvascular growth [38], postnatal vasculogenesis 
[58], glomeruloid angiogenesis [59] and vessel 
co-option [4]. Both from our group and from others 
there is a growing body of evidence that these 
non-sprouting vascularization mechanisms can 
interfere with the efficacy of the current 
antiangiogenic treatments [13, 60-63]. Therefore, our 
current studies using subcutaneous models (where 
sprouting angiogenesis dominates) need to be 
extended into studies utilizing both orthotopic 
primary tumors of different origin and metastatic 
animal models in order to fully explore the potential 
of the platform presented in the current manuscript.  
In conclusion, the therapeutic efficacy of 
antiangiogenic RTKIs is critically determined by their 
intratumoral distribution. Our current findings 
demonstrate the potential of MALDI-MSI to help in 
optimizing the dose and schedule and thus the 
antivascular and antitumor effects of RTKIs. This 
potential of MALDI-MSI to study the localization of 
unlabelled small molecule antiangiogenic RTKIs in 
malignant tumors is of crucial importance because 
there is a pressing need for biomarkers of 
anti-angiogenic therapy in the clinics [64]. 
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